00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
21:34 , Jun 23, 2017 |  BioCentury  |  Emerging Company Profile

TRuCs vs. CARs

TCR2 Therapeutics Inc. is creating autologous T cell therapies that it thinks will have greater activity against solid tumors than CAR T therapies, and broader applicability than TCR therapies. The key to the approach is...
07:00 , Sep 19, 2016 |  BioCentury  |  Emerging Company Profile

Solid CARs

Long-standing doubts about whether CAR T cells would be effective against solid tumors were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso showed no complete or partial responses...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

CAR-T-meso: Phase I data

Data from 5 patients with mesothelin-expressing tumors in a U.S. Phase I trial showed that a single infusion of 1-3*107 CAR-T-meso cells/m 2 was well tolerated with no off-tumor on-target toxicities reported. Grade 4 adverse...
07:00 , Apr 27, 2015 |  BioCentury  |  Product Development

CAR window

MaxCyte Inc. is collaborating with the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University to develop transiently expressed chimeric antigen receptor T cell therapies that may allow better control over the cells' therapeutic...
07:00 , Apr 27, 2015 |  BioCentury  |  Finance

CAR talk

While investors in Kite Pharma Inc. (NASDAQ:KITE) and Juno Therapeutics Inc. (NASDAQ:JUNO) will soon be combing through American Society of Clinical Oncology abstracts, they shouldn't hold their breath for efficacy data for the CAR T...
02:19 , Apr 22, 2015 |  BC Extra  |  Company News

MaxCyte, JHU partner for preclinical CARs

MaxCyte Inc. (Gaithersburg, Md.) partnered with The Johns Hopkins University (Baltimore, Md.) to develop chimeric antigen receptor (CAR) T cell therapies to treat solid tumors based on MaxCyte's mRNA technology that results in transient expression...
01:38 , Apr 21, 2015 |  BC Extra  |  Top Story

CAR T stocks fall on solid tumor data

CAR T data from Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania demonstrated much of what's already known about the challenges of moving the technology into the solid tumor setting. A presentation at the...